Hot Features
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in th... SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3.9704 | 536.830719308 | 0.7396 | 5.71 | 0.7036 | 180482 | 2.50694333 | CS |
| 4 | 3.7524 | 391.854636591 | 0.9576 | 5.71 | 0.6328 | 383943 | 0.94860302 | CS |
| 12 | 3.81 | 423.333333333 | 0.9 | 5.71 | 0.6328 | 556030 | 0.95105205 | CS |
| 26 | 4.04 | 602.985074627 | 0.67 | 5.71 | 0.57789 | 488144 | 0.83910189 | CS |
| 52 | 3.78 | 406.451612903 | 0.93 | 5.71 | 0.565 | 424831 | 0.81414251 | CS |
| 156 | 2.23 | 89.9193548387 | 2.48 | 5.71 | 0.565 | 293422 | 1.40314805 | CS |
| 260 | -3.34 | -41.4906832298 | 8.05 | 8.73 | 0.565 | 345757 | 2.55918015 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.